Analyst Price Target is $13.50
▲ +500.00% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $13.50, with a high forecast of $17.50 and a low forecast of $11.00. The average price target represents a 500.00% upside from the last price of $2.25.
Current Consensus is
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Vor Biopharma. This Buy consensus rating has held steady for over two years.
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More